Magnetic resonance imaging of multifunctional pluronic stabilized iron-oxide nanoparticles in tumor-bearing mice.

Magnetic resonance imaging of multifunctional pluronic stabilized iron-oxide nanoparticles in tumor-bearing mice.
复制标题

DOI:
10.1016/j.biomaterials.2009.08.042
复制
发表时间:
2009-12
期刊:
影响因子:
14
通讯作者:
Labhasetwar, Vinod
Labhasetwar, Vinod
中科院分区:
工程技术1区
文献类型:
--
作者:
Jain, Tapan K.;Foy, Susan P.;Erokwu, Bernadette;Dimitrijevic, Sanja;Flask, Christopher A.;Labhasetwar, Vinod

文献摘要

参考文献

被引文献

相似文献

我们正在研究磁性纳米颗粒(MNP)的磁共振成像特性,该磁性纳米颗粒由涂覆有油酸(OA)的氧化铁磁性核组成,然后用普朗尼克或特尼克嵌段共聚物稳定。由于普朗尼克和四电子在结构上不同,并且在疏水性的比例上也不同,(聚[环氧丙烷])和亲水性(聚[环氧乙烷])链段在聚合物链和分子量上的差异,假设它们锚定到围绕磁芯的OA涂层上可以显著影响MNP的物理性质,静脉内给药后它们与生物环境的相互作用,以及定位于肿瘤的能力。嵌段共聚物与MNP的量被认为取决于它们的分子结构,并影响MNP的特性。普朗尼克F127修饰的MNP在整个肿瘤中表现出持续和增强的对比度,而菲立磁IV的对比度是短暂的,仅限于肿瘤周边。总之,我们的pluronic F127包被的MNP,其也可以负载抗癌剂用于药物递送,可以被开发为有效的癌症治疗诊断剂,即具有组合的药物递送和成像特性的试剂。
We are investigating the magnetic resonance imaging characteristics of magnetic nanoparticles (MNPs) that consist of an iron-oxide magnetic core coated with oleic acid (OA), then stabilized with a pluronic or tetronic block copolymer. Since pluronics and tetronics vary structurally, and also in the ratio of hydrophobic (poly[propylene oxide]) and hydrophilic (poly[ethylene oxide]) segments in the polymer chain and in molecular weight, it was hypothesized that their anchoring to the OA coating around the magnetic core could significantly influence the physical properties of MNPs, their interactions with biological environment following intravenous administration, and ability to localize to tumors. The amount of block copolymer associated with MNPs was seen to depend upon their molecular structures and influence the characteristics of MNPs. Pluronic F127-modified MNPs demonstrated sustained and enhanced contrast in the whole tumor, whereas that of Feridex IV was transient and confined to the tumor periphery. In conclusion, our pluronic F127-coated MNPs, which can also be loaded with anticancer agents for drug delivery, can be developed as an effective cancer theranostic agent, i.e. an agent with combined drug delivery and imaging properties.
DOI: 10.1016/s0168-3659(96)01504-0
发表时间: 1997-02-01
影响因子: 10.8
作者:
Dunn, SE;Coombes, AGA;Illum, L
通讯作者: Illum, L
DOI: 10.1021/ja072210i
发表时间: 2007-10-24
影响因子: 15
作者:
Lee, Haerim;Yu, Mi Kyung;Jon, Sangyong
通讯作者: Jon, Sangyong
DOI: 10.1586/14737175.8.10.1507
发表时间: 2008-10-01
影响因子: 4.3
作者:
Weber, Marc-Andre;Giesel, Frederik Lars;Stieltjes, Bram
通讯作者: Stieltjes, Bram
DOI: 10.1259/bjr/41321492
发表时间: 2006-01-01
影响因子: 2.6
作者:
Khoo, V. S.;Joon, D. L.
通讯作者: Joon, D. L.
DOI: 10.1021/mp7001285
发表时间: 2008-03-01
影响因子: 4.9
作者:
Jain, Tapan K.;Reddy, Maram K.;Labhasetwar, Vinod
通讯作者: Labhasetwar, Vinod